Solid Tumor Unknown Status Phase 1 Trials for Tislelizumab (DB14922)

Also known as: Cancer - Solid Tumors / Solid Tumour / Solid Tumours / Tumor, Solid / Solid Neoplasms / Solid tumour/cancer / Solid Cancers / Cancer: Solid Tumors / Neoplasms, Solid Tumor / Cancer, Solid Tumor / Tumors, Solid / Solid Tumor Cancer / Solid Tumors or Cancers / Solid Tumors / Solid Neoplasm / Cancer (Solid Tumors) / Solid Tumor Neoplasms / Solid Tumor Cancers / Solid Cancer / Neoplasm / Neoplasm (morphologic abnormality) / Neoplasms of unspecified behavior / Neoplasms NOS / Neoplasms NOS (disorder) / [M]Neoplasms NOS (morphologic abnormality) / Neoplasm (NOS) / Tumor / Neoplasm NOS / Tumour / Tumour NOS / Neoplasms / Tumour, NOS / Tumor NOS / Neoplasm, NOS / Tumor, NOS / Neoplasms benign, malignant and unspecified (incl cysts and polyps)

IndicationStatusPhase
DBCOND0030180 (Solid Tumor)Unknown Status1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT05798533
Neo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03)Treatment
NCT05833984
Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and LymphomasTreatment
NCT05906524
KD6001 in Combination With Anti-PD-1 Antibody±Bevacizumab in Patients With Advanced HCC and Other Solid TumorsTreatment